CellaVision AB (publ) (STO:CEVI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 2.92B -19.4% |
| Revenue (ttm) | 730.59M -2.3% |
| Net Income | 134.07M -11.9% |
| EPS | 5.62 -11.9% |
| Shares Out | 23.85M |
| PE Ratio | 21.81 |
| Forward PE | 19.18 |
| Dividend | 2.75 (2.27%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 49,877 |
| Average Volume | 61,203 |
| Open | 124.20 |
| Previous Close | 122.60 |
| Day's Range | 122.60 - 126.40 |
| 52-Week Range | 120.00 - 208.00 |
| Beta | 0.95 |
| RSI | 29.13 |
| Earnings Date | Apr 24, 2026 |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox... [Read more]
Financial Performance
In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.
Financial StatementsNews
CellaVision AB (CLVSF) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
CellaVision AB (CLVSF) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Q1 2026 CellaVision AB Earnings Call Transcript
Q1 2026 CellaVision AB Earnings Call Transcript
CellaVision AB Earnings Call Transcript: Q1 2026
Q1 revenue fell 14.6% year-over-year due to EMEA inventory adjustments, while Americas and APAC delivered strong growth. New product launches and a major software upgrade are expected to drive H2 recovery, with EMEA sales seen improving in Q2.
CellaVision AB Earnings Call Transcript: Q4 2025
Q4 2025 saw robust growth in the Americas and EMEA, offsetting a softer APAC, with full-year organic growth at 9%. Strategic milestones included a CE Mark for the bone marrow application and a major software upgrade, while a dividend increase to SEK 2.75 per share is proposed.
CellaVision AB Earnings Call Transcript: Q3 2025
Net sales declined 1.7% to SEK 176 million, but organic growth was 2.6% year-over-year, with EBITDA margin rising to 28%. Strategic milestones include a completed clinical trial and software upgrade, while regional performance was mixed and APAC showed lumpy but positive trends.
CellaVision AB Earnings Call Transcript: Q2 2025
Q2 2025 saw robust results with SEK 191 million revenue and nearly 8% organic growth, led by APAC. Gross margin rose to 68%, and EBITDA margin was 31%. Strategic launches and R&D investments continue, with the bone marrow module set for 2026 commercial launch.
CellaVision AB Earnings Call Transcript: Q1 2025
Revenue grew 14% year-over-year to SEK 195 million, with strong gross margin at 70% and robust growth across all regions and product lines. Increased R&D investment and strategic partnerships are driving innovation and market share gains, while FX and competitive pressures remain key risks.
CellaVision AB Earnings Call Transcript: Q4 2024
Q4 2024 saw mixed regional results: strong APAC growth, modest EMEA, and a decline in Americas, leading to -7% organic growth. Gross margin was 69% and EBITDA margin 33%. Strategic partnership with Sysmex and ongoing innovation investments position the company for recovery and future growth.
CellaVision AB Earnings Call Transcript: Q3 2024
Q3 delivered 9% organic revenue growth, led by record EMEA sales and improved gross margin, while Americas faced a 20% decline due to political uncertainty. R&D investment rose to 22% of sales, with key product launches and regulatory milestones on track for 2025.
CellaVision AB Earnings Call Transcript: Q2 2024
Q2 saw 11% revenue growth and a 32% EBITDA margin, with APAC delivering record results and EMEA showing steady gains. Operational issues in Americas are seen as temporary, while price increases and innovation investments are set to boost margins and growth in H2 2024.